2011
DOI: 10.3111/13696998.2011.584096 View full text |Buy / Rent full text
|
|

Abstract: Patients with resected SCCHN incur substantial healthcare costs and have high utilization rates. Results of this analysis are primarily applicable to resected SCCHN in a managed-care setting, and therefore may not be generalizable to the entire US population. Furthermore, disease stage is an important factor impacting outcomes, but these analyses did not stratify patients according to disease stage.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
2
1
0
22
0

Year Published

2014
2014
2014
2014

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

0
22
0
Order By: Relevance
“…Most (nine of 12) have used commercial or publically available US databases of administrative claims [9, 20, 34, 38, 41, 50, 54, 55, 78], with one each using the Hospital Episode Statistic (HES) database in the UK [37], hospital records from five Dutch university hospitals [69], or a regional cancer center in Brazil [51]. Time horizons, databases, demographic and disease subpopulations, and costing years have ranged widely, hindering comparisons.…”
Section: Resultsmentioning
“…These studies encompass two in the USA [9, 20] and one each in the UK [37], Brazil [51], and the Netherlands [69]. In the USA, annual attributable costs to a payer may range from US$5–35,000, depending on the way the population is defined.…”
Section: Resultsmentioning
See 1 more Smart Citation
“…4 The healthcare cost expenditure for post-surgical head and neck cancer patients nearly triples after their index diagnosis. 8 With the care of head and neck cancer patients already being more expensive than the care of most other cancers, 4 consideration of cost should increasingly play a role in deciding among treatments of comparative effectiveness.…”
Section: Discussionmentioning
“…Recent studies have used insurance claims data to identify costs, 4,8,9 focusing either on disease type 4,9 or treatment type. 8 While having the advantage of determining actual cost, relying on claims coding to identify patients and treatments is not without fault; 24.5% to 67.1% of patients identified by a diagnosis of cancer had no consequent identifiable treatment. 4,9,10 …”
Section: Discussionmentioning